

Diagnostic RCTs

Madhukar Pai
Associate Professor
McGill University, Montreal

madhukar.pai@mcgill.ca

Very few diagnostic RCTs in TB

- ▶ Whatever little we have, is all new!!
 - ▶ A few on active case detection
 - ▶ A trial on same-day smear diagnosis (TDR)
 - ▶ A trial on Xpert MTB/RIF in South Africa
 - ▶ Ongoing trials on Xpert MTB/RIF
 - ▶ Cluster-randomized stepped wedge designs for phased implementation





Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial

Elizabeth L Corbett, Tsitsi Bandason, Trinh Duong, Ethel Dauya, Beauty Makamure, Gavin J Churchyard, Brian G Williams, Shungu S Munyati, Anthony E Butterworth, Peter R Mason, Stanley Mungofa, Richard J Hayes

Summary

Lancet 2010; 376: 1244–53

Published Online

October 4, 2010

DOI:10.1016/S0140-

6736(10)61425-0

See Comment page 1205

Clinical Research Unit

(E L Corbett PhD,

Prof A E Butterworth PhD) and

Infectious Disease

Epidemiology Unit

(T Duong MSc,

Prof R J Hayes DSc), London

School of Hygiene and Tropical

Medicine, London, UK;

Biomedical Research and

Training Institute, Harare,

Zimbabwe (E L Corbett,

T Bandason MSc, E Dauya BCom,

B Makamure BTEch,

S S Munyati MSc

Prof A E Butterworth,

Prof P R Mason PhD); Aurum

Institute, Johannesburg, South

Africa (Prof G J Churchyard PhD);

South African Centre for

Epidemiology and

Mathematical Analysis

(SACEMA), University of

Stellenbosch, South Africa

(Prof B G Williams PhD);

Department of Medical

Laboratory Sciences, College of

Health Sciences, University of

Background Control of tuberculosis in settings with high HIV prevalence is a pressing public health priority. We tested two active case-finding strategies to target long periods of infectiousness before diagnosis, which is typical of HIV-negative tuberculosis and is a key driver of transmission.

Methods Clusters of neighbourhoods in the high-density residential suburbs of Harare, Zimbabwe, were randomised to receive six rounds of active case finding at 6-monthly intervals by either mobile van or door-to-door visits. Randomisation was done by selection of discs of two colours from an opaque bag, with one disc to represent every cluster, and one colour allocated to each intervention group before selection began. In both groups, adult (≥ 16 years) residents volunteering chronic cough (≥ 2 weeks) had two sputum specimens collected for fluorescence microscopy. Community health workers and cluster residents were not masked to intervention allocation, but investigators and laboratory staff were masked to allocation until final analysis. The primary outcome was the cumulative yield of smear-positive tuberculosis per 1000 adult residents, compared between intervention groups; analysis was by intention to treat. The secondary outcome was change in prevalence of culture-positive tuberculosis from before intervention to before round six of intervention in 12% of randomly selected households from the two intervention groups combined; analysis was based on participants who provided sputum in the two prevalence surveys. This trial is registered, number ISRCTN84352452.

Findings 46 study clusters were identified and randomly allocated equally between intervention groups, with 55 741 adults in the mobile van group and 54 691 in the door-to-door group at baseline. HIV prevalence was 21% (1916/9060) and in the 6 months before intervention the smear-positive case notification rate was 2.8 per 1000 adults per year. The trial was completed as planned with no adverse events. The mobile van detected 255 smear-positive patients from 5466 participants submitting sputum compared with 137 of 4711 participants identified through door-to-door visits (adjusted risk ratio 1.48, 95% CI 1.11–1.96, $p=0.0087$). The overall prevalence of culture-positive tuberculosis declined from 6.5 per 1000 adults (95% CI 5.1–8.3) to 3.7 per 1000 adults (2.6–5.0; adjusted risk ratio 0.59, 95% CI 0.40–0.89, $p=0.0112$).

Interpretation Wide implementation of active case finding, particularly with a mobile van approach, could have rapid effects on tuberculosis transmission and disease.

Twelve-monthly versus six-monthly radiological screening for active case-finding of tuberculosis: a randomised controlled trial

Gavin J Churchyard,^{1,2} Katherine Fielding,² Surita Roux,¹ Elizabeth L Corbett,³ Richard E Chaisson,⁴ Kevin M De Cock,³ Richard J Hayes,² Alison D Grant³

¹Aurum Institute for Health Research, Johannesburg, South Africa

²Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

³Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK

⁴Center for TB Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA

Correspondence to

Professor G J Churchyard, Aurum Institute for Health Research, PostNet Suite 300, Private Bag X30500, Houghton 2041, South Africa; gchurchyard@auruminstitute.org

Received 18 March 2010
Accepted 7 October 2010

ABSTRACT

Background The incidence of tuberculosis has increased among South African gold miners despite comprehensive control programmes, including a radiological screening programme. No data are available as to the optimal frequency of screening. The aim of this study was to compare 6-monthly and 12-monthly radiological screening for active tuberculosis case-finding.

Methods Employees of a gold mining company were randomly assigned to the control arm (screening at baseline, 12 and 24 months) or the intervention arm (additional 'intervention' radiographs at 6 and 18 months after baseline). Study outcomes included proportion of tuberculosis cases detected by screening, proportion smear-positive, extent of disease and mortality.

Results 22 634 miners were randomised. Compared with 12-monthly screening, 6-monthly screening detected more tuberculosis suspects but not more cases, partly due to greater attrition between screening and further investigation after 'intervention' compared with routine radiographs. Tuberculosis cases detected in the 6-monthly versus the 12-monthly screening arm had less extensive disease ($p=0.05$) and a lower tuberculosis-specific mortality (death on tuberculosis treatment) (2.1 and 2.8 per 1000 person-years respectively, HR 0.73, 95% CI 0.50 to 1.08, $p=0.1$), which was most marked in the first 2 months of treatment (HR 0.48, 95% CI 0.23 to 0.98, $p=0.04$) when death from tuberculosis is most likely.

Discussion In settings with a high prevalence of HIV and tuberculosis despite standard tuberculosis control measures, more frequent case-finding may reduce the extent of disease, tuberculosis mortality and tuberculosis transmission through earlier detection of active tuberculosis cases. To be effective, however, all tuberculosis suspects identified through screening must be investigated for tuberculosis.

programmes^{6–9} that include active case-finding using radiological screening as well as passive case-finding and treatment with fixed-dose combination tables taken under direct observation for the entire treatment period, tuberculosis rates among miners rose during the 1990s to over 3000 per 100 000 per year by 1999.⁸ Silica dust exposure and silicosis are both risk factors for tuberculosis.^{10–17} Silicosis occurs commonly among gold miners, so that miners now have a high prevalence of two of the most powerful risk factors for developing tuberculosis disease following infection (silicosis and HIV), and their combined effect is multiplicative.¹⁶

Radiological screening has been used in the gold mining industry for decades¹⁸; both 6- and 12-monthly radiological screening were used in different companies, with no data concerning the most effective screening frequency, particularly in the context of high HIV prevalence. Earlier detection of tuberculosis could reduce tuberculosis-specific morbidity, particularly chronic lung sequelae, mortality and the duration of infectiousness. In support of this, observational studies have demonstrated significantly less extensive radiological disease¹⁹ and lower case fatality rates among tuberculosis cases detected by the radiological screening programme compared with those who self-presented with symptoms.⁷ However, no trial has previously investigated the optimal frequency of active tuberculosis case-finding using radiological screening.

The aim of this trial was to compare the individual level effect of 6-monthly versus 12-monthly radiological screening on the proportion of tuberculosis cases detected by screening, the proportion who were smear-positive, the extent of the disease and mortality.

A Multi-Country Non-Inferiority Cluster Randomized Trial of Frontloaded Smear Microscopy for the Diagnosis of Pulmonary Tuberculosis

Luis Eduardo Cuevas^{1,2*}, Mohammed Ahmed Yassin¹, Najla Al-Sonboli³, Lovett Lawson⁴, Isabel Arbide⁵, Nasher Al-Aghbari⁶, Jeevan Bahadur Sherchand⁷, Amin Al-Absi⁶, Emmanuel Nnamdi Emenyonu⁴, Yared Merid⁸, Mosis Ifenyi Okobi⁹, Juliana Olubunmi Onuoha⁴, Melkamsew Aschalew⁸, Abraham Aseffa¹⁰, Greg Harper¹, Rachel Mary Anderson de Cuevas¹, Kristin Kremer¹¹, Dick van Soolingen¹¹, Carl-Michael Nathanson², Jean Joly², Brian Faragher¹, Stephen Bertel Squire¹, Andrew Ramsay²

1 Liverpool School of Tropical Medicine, Liverpool, United Kingdom, **2** United Nations Children's Fund/United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland, **3** Medical Faculty, Sana'a University, Sana'a, Yemen, **4** Zankli Medical Center, Abuja, Nigeria, **5** Bushullo Major Health Centre, Awassa, Ethiopia, **6** National Tuberculosis Institute, Sana'a, Yemen, **7** Tribhuvan University Institute of Medicine, Kathmandu, Nepal, **8** Southern Region Health Bureau, Awassa, Ethiopia, **9** Wuse General Hospital, Abuja, Nigeria, **10** Armauer Hansen Research Institute, Addis Ababa, Ethiopia, **11** Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, The Netherlands

Abstract

Background: More than 50 million people around the world are investigated for tuberculosis using sputum smear microscopy annually. This process requires repeated visits and patients often drop out.


Methods and Findings: This clinical trial of adults with cough ≥ 2 wk duration (in Ethiopia, Nepal, Nigeria, and Yemen) compared the sensitivity/specificity of two sputum samples collected "on the spot" during the first visit plus one sputum sample collected the following morning (spot-spot-morning [SSM]) versus the standard spot-morning-spot (SMS) scheme. Analyses were per protocol analysis (PPA) and intention to treat (ITT). A sub-analysis compared just the first two smears of each scheme, spot-spot and spot-morning. In total, 6,627 patients (3,052 SSM/3,575 SMS) were enrolled; 6,466 had culture and 1,526 were culture-positive. The sensitivity of SSM (ITT, 70.2%, 95% CI 66.5%–73.9%) was non-inferior to the sensitivity of SMS (PPA, 65.9%, 95% CI 62.3%–69.5%). Similarly, the specificity of SSM (ITT, 96.9%, 95% CI 93.2%–99.9%) was non-inferior to the specificity of SMS (ITT, 97.6%, 95% CI 94.0%–99.9%). The sensitivity of spot-spot (ITT, 63.6%, 95% CI 59.7%–67.5%) was also non-inferior to spot-morning (ITT, 64.8%, 95% CI 61.3%–68.3%), as the difference was within the selected –5% non-inferiority limit (difference ITT = 1.4%, 95% CI –3.7% to 6.6%). Patients screened using the SSM scheme were more likely to provide the first two specimens than patients screened with the SMS scheme (98% versus 94.2%, $p < 0.01$). The PPA and ITT analysis resulted in similar results.

Conclusions: The sensitivity and specificity of SSM are non-inferior to those of SMS, with a higher proportion of patients submitting specimens. The scheme identifies most smear-positive patients on the first day of consultation.

Trial Registration: Current Controlled Trials ISRCTN53339491

Please see later in the article for the Editors' Summary.

A randomised controlled trial of point-of-treatment GeneXpert MTB/RIF Assay for the diagnosis of TB at primary care clinics in high HIV prevalence resource limited settings



Stepped wedge design

- ▶ Unidirectional cross-over
- ▶ All transfer from control to intervention, but at different times
- ▶ Randomization of order of transfer
 - ▶ More than one cluster may transfer at once
 - ▶ Restrained in case of small number of clusters
- ▶ Need even more time than in regular cross-over design

cluster study period

	1	2	3	4	5
1	Control	Intervention	Intervention	Intervention	Intervention
2	Control	Control	Intervention	Intervention	Intervention
3	Control	Control	Control	Intervention	Intervention
4	Control	Control	Control	Control	Intervention


Example stepped wedge design

- ▶ Trial of GeneXpert in Brazil
 - ▶ Rio de Janeiro and Manaus
- ▶ 14 clusters = defined areas in which all health care units send in samples to same laboratory for diagnosis of TB
- ▶ GeneXpert used instead of smear microscopy (and culture)
- ▶ Transfer from smear to GeneXpert in 7 steps
- ▶ Main effects studied:
 - ▶ Diagnosis and treatment registration of bacteriologically confirmed pulmonary TB, overall and for HIV+ individuals
 - ▶ Proportion of TB patients diagnosed with MDR
 - ▶ Time to appropriate treatment after diagnosis for (MDR) TB patients
 - ▶ Cost-effectiveness
 - ▶ (Treatment outcomes)

Methodological issues in dx RCTs



GRADE: for high quality evidence, impact on patient-important outcomes needs to be demonstrated



Distraction From Randomization in Diagnostic Research

CORNELIS J. BIESHEUVEL, PHD, DIEDERICK E. GROBBEE, MD, PHD,
AND KAREL G.M. MOONS, PHD

The ultimate goal of medical care, including diagnostic testing, is to improve patient outcome. Accordingly, it has been advocated widely that when establishing a test's diagnostic accuracy, the impact of the test on patient outcome subsequently must be quantified. When studying patient outcome in medical research, the use of randomized comparisons comes into perspective. In our view, randomized studies often are not necessary to validly estimate the effect of the diagnostic test on patient outcome. Results of cross-sectional diagnostic studies, combined with results from therapeutic studies, often will suffice.
Ann Epidemiol 2006;16:540–544. © 2006 Elsevier Inc. All rights reserved.

When performing a randomized trial to determine the impact of a diagnostic test or strategy on patient outcome, an initially *diagnostic* research question is transformed into *therapeutic* research question (with the goal of establishing causality) with corresponding consequences for the design of the study. A disadvantage of a randomized approach to directly quantify the contribution of a diagnostic test and treatment on patient outcome is that it often addresses diagnosis and treatment as a single combined strategy, a “package deal.” This makes it impossible to determine afterwards whether a positive effect on patient outcome was attributed solely to the improved diagnosis by using the test under study or to the chosen (new) treatment strategies.






FIGURE 1. In the first phases of evaluating a new test, technical feasibility and diagnostic performance (is the test able to discriminate diseased from nondiseased?) are assessed (1–4). Subsequently, the value of the test to detect a particular disease is obtained by a cross-sectional study in which the diagnostic accuracy of the new test is compared with the current reference test. The information obtained by this study can be combined with information obtained from randomized controlled trials that evaluated the effect of a therapeutic strategy for that disease on patient outcome. By combining results of both studies, one can easily quantify the value of the diagnostic test to improve patient outcome.

When Is Measuring Sensitivity and Specificity Sufficient To Evaluate a Diagnostic Test, and When Do We Need Randomized Trials?

Sarah J. Lord, MBBS, MS; Les Irwig, MBBCh, PhD; and R. John Simes, MBBS, MS, MD

The clinical value of using a new diagnostic test depends on whether it improves patient outcomes beyond the outcomes achieved using an old diagnostic test. When can studies of diagnostic test accuracy provide sufficient information to infer clinical value, and when do clinicians need to wait for results from randomized trials? The authors argue that accuracy studies suffice if a new diagnostic test is safer or more specific than, but of similar sensitivity to, an old test. However, if a new test is more sensitive than an old test, it leads to the detection of extra cases of disease. Results from treatment trials that enrolled only patients detected by

the old test may not apply to these extra cases. Clinicians need to wait for results from randomized trials assessing treatment efficacy in cases detected by the new diagnostic test, unless they can be satisfied that the new test detects the same spectrum and subtype of disease as the old test or that treatment response is similar across the spectrum of disease.


Ann Intern Med. 2006;144:850-855.

For author affiliations, see end of text.

www.annals.org




Figure 1. Trial evidence versus linked evidence of test accuracy and treatment efficacy.



*Cases detected by the new and old test may not show similar response to treatment.

RCT always needed?



Using the Principles of Randomized Controlled Trial Design to Guide Test Evaluation

Sarah J. Lord, MBBS, MS, Les Irwig, MBBCh, PhD, Patrick M. M. Bossuyt, PhD

The decision to use a new test should be based on evidence that it will improve patient outcomes or produce other benefits without adversely affecting patients. In principle, long-term randomized controlled trials (RCTs) of test-plus-treatment strategies offer ideal evidence of the benefits of introducing a new test relative to current best practice. However, long-term RCTs may not always be necessary. The authors advocate using the hypothetical RCT as a conceptual framework to identify what types of comparative evidence are needed for test evaluation. Evaluation begins by stating the major claims for the new test and determining whether it will be used as a replacement, add-on, or triage test to achieve these claims. A flow diagram of this hypothetical RCT is constructed to show the essential design elements, including population, prior tests, new test

*and existing test strategies, and primary and secondary outcomes. Critical steps in the pathway between testing and patient outcomes, such as differences in test accuracy, changes in treatment, or avoidance of other tests, are displayed for each test strategy. All differences between the tests at these critical steps are identified and prioritized to determine the most important questions for evaluation. Long-term RCTs will not be necessary if it is valid to use other sources of evidence to address these questions. Validity will depend on issues such as the spectrum of patients identified by the old and new test strategies. **Key words:** diagnostic techniques and procedures/standards; sensitivity and specificity; randomized controlled trials as topic; outcome assessment (health care). (*Med Decis Making* 2009;29:E1–E12)*




Some issues..

- ▶ Actions after each possible test results must follow a clear unambiguous protocol
- ▶ Sample sizes may be large
- ▶ Diversity and complexity of diagnostic process leads to infinite number of possible trials
- ▶ Ethical questions
 - ▶ OK to randomize to an experimental test?
 - ▶ E.g. Not FDA or WHO approved
 - ▶ Once a test is WHO-approved and is shown to be superior to conventional test, OK to deny to half of trial participants?



Sample size calculations for test-treatment randomised controlled trials.



Ferrante di Ruffano L et al. *BMJ* 2012;344:bmj.e686

“The figure identifies those participants who contribute statistical power in a randomised trial comparing two tests (where the difference in outcome originates entirely from a difference in diagnostic accuracy). Test 2 has higher sensitivity than test 1 (difference shown in A). Test 2 also has higher specificity than test 1 (difference shown in B). Different widths of diseased and non-diseased columns indicate the prevalence of disease in the study sample. Only participants in A and B would have different test results if they received test 2 rather than test 1 and therefore the potential for different outcomes (all other participants in the study would have the same test result, irrespective of which test they were allocated to). Statistical power therefore depends on only the numbers of participants in A and B (particularly A)”

Diagnostic RCT: Xpert MTB/RIF in the clinic

Grant Theron and Jonny Peter
on behalf of the TB-NEAT consortium
(PI: Keertan Dheda)
Lung Infection and Immunity Unit,
University of Cape Town, South Africa


TB NEAT



A RCT of a point-of-treatment Xpert MTB/RIF for the diagnosis of TB at primary care clinics in HIV prevalent, resource-limited settings.

- ▶ We don't know the impact of Xpert on patient health, or if it feasible to do the assay the clinic
- ▶ **Hypothesis:** One sputum Xpert MTB/RIF performed at the point-of-treatment will improve TB-related morbidity and patient-level costs in individuals suspected of TB who present to primary level clinics in high burden, HIV-prevalent settings.
- ▶ **Setting and patient numbers:**
 1. 5 study sites in 4 countries (Cape Town, Durban, Harare, Lusaka, Mbeya)
 2. Enrolment target of approximately 1600 patients (March 2011 – February 2012)
 3. Patients are recruited from (peri)-urban primary care clinics. An Xpert assay is performed on site by a study nurse.

Xpert RCT: Patient flow




Each patient also receives: (i) TB-related morbidity score (at 0, 2 and 6 months), (ii) a health and cost questionnaire (0, 2 and 6 months), (iii) a CXR at 0 months and at follow-up if symptomatic

→ Patients who are TB positive are referred to the DOTS programme at the clinic

Xpert RCT: Ethical considerations

- Xpert is more accurate than smear – can we justify giving half our patients an inferior test?
 - ▶ Culture in both arms
 - ▶ Hardly any data on if 2-3 weeks difference in treatment initiation in a clinic makes a difference
 - ▶ Xpert is not the standard-of-care yet in most countries
 - ▶ The same day smear-result and CXRs are benefits patients do not receive upfront in routine care

Xpert RCT: Ethical and other challenges in a rapidly moving field



→ Approx. 4 new Xpert publications per month!

Conclusions

- ▶ Balancing scientific rigor with practical constraints in difficult (especially in multicenter studies)
- ▶ Maintaining relevance in a rapidly changing landscape can be hard
- ▶ Patient outcomes are not just dependent on diagnosis → important to keep in mind that a diagnostic + treatment package is often evaluated
- ▶ Measuring long-term patient outcomes (e.g. morbidity) can require large patient numbers

